The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial)

• Published in: European journal of surgical oncology Vol. 50; no. 6; p. 108265
• Main Authors: Holmberg, Carl-Jacob, Zijlker, Lisanne P., Katsarelias, Dimitrios, Huibers, Anne E., Wouters, Michel W.J.M., Schrage, Yvonne, Reijers, Sophie J.M., van Thienen, Johannes V., Grünhagen, Dirk J., Martner, Anna, Nilsson, Jonas A., van Akkooi, Alexander C.J., Ny, Lars, van Houdt, Winan J., Olofsson Bagge, Roger
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2024
• Subjects: Anti-PD1; Cancer and Oncology; Cancer och onkologi; In-transit metastases; Isolated limb perfusion; Melanoma; In-transit metastases; Anti-PD1; Melanoma; Isolated limb perfusion
• ISSN: 0748-7983; 1532-2157; 1532-2157
• DOI: 10.1016/j.ejso.2024.108265

ILP has shown to achieve high response rates in patients with melanoma ITM. Possibly there is a synergistic mechanism of action of ILP and anti-PD1. The aim of this trial was to investigate the safety and efficacy of adding a single dose of systemic anti-PD1 to isolated limb perfusion (ILP) for patients with melanoma in-transit metastases (ITM). In this placebo controlled double-blind phase Ib/II trial, patients with melanoma ITM were randomized 1:1 to either a single systemic dose of nivolumab or placebo one day prior to ILP. The primary endpoint was complete response (CR) rate at three months, and safety in terms of incidence and severity of adverse events (AEs). A total of 20 patients were included. AEs of any grade occurred in 90% of patients in the nivolumab arm and in 80% in the placebo arm within three months after ILP. Grade 3 AEs were reported in 40% and 30% respectively, most commonly related to wound infection, wound dehiscence, or skin necrosis. There were no grade 4 or 5 AEs reported. The CR rate was 75% in the nivolumab arm and 60% in the placebo arm. The 1-year local progression-free rate was 86% in the nivolumab arm and 67% in the placebo arm. The 1-year OS was 100% in both arms. For patients with melanoma ITM, the addition of a single systemic dose of nivolumab the day before ILP is considered safe and feasible with promising efficacy. Accrual will continue in a phase 2 trial.